Cinctive Capital Management LP Buys Shares of 105,228 Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Cinctive Capital Management LP acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 105,228 shares of the company's stock, valued at approximately $2,364,000. Cinctive Capital Management LP owned 0.15% of Nurix Therapeutics as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio increased its stake in Nurix Therapeutics by 3.7% in the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company's stock valued at $747,000 after buying an additional 1,820 shares during the period. GAMMA Investing LLC boosted its position in Nurix Therapeutics by 299.8% during the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company's stock valued at $95,000 after purchasing an additional 3,424 shares during the last quarter. SG Americas Securities LLC grew its stake in Nurix Therapeutics by 365.0% in the second quarter. SG Americas Securities LLC now owns 103,199 shares of the company's stock valued at $2,154,000 after purchasing an additional 81,005 shares in the last quarter. Bank of New York Mellon Corp increased its position in Nurix Therapeutics by 31.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 209,136 shares of the company's stock worth $4,365,000 after purchasing an additional 49,918 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Nurix Therapeutics by 762.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,207 shares of the company's stock worth $317,000 after purchasing an additional 13,444 shares during the last quarter.

Insiders Place Their Bets

In other news, insider Christine Ring sold 3,290 shares of the company's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $25.00, for a total value of $82,250.00. Following the sale, the insider now owns 24,592 shares of the company's stock, valued at approximately $614,800. This represents a 11.80 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Houte Hans Van sold 2,368 shares of the firm's stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total transaction of $57,542.40. Following the sale, the chief financial officer now directly owns 37,270 shares of the company's stock, valued at approximately $905,661. The trade was a 5.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,401 shares of company stock worth $437,453 over the last 90 days. Corporate insiders own 9.80% of the company's stock.

Nurix Therapeutics Stock Performance

NASDAQ NRIX traded down $0.66 during midday trading on Tuesday, hitting $20.83. The company had a trading volume of 312,434 shares, compared to its average volume of 899,746. The firm has a fifty day simple moving average of $24.02 and a two-hundred day simple moving average of $21.84. Nurix Therapeutics, Inc. has a fifty-two week low of $6.58 and a fifty-two week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The firm had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. Equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on NRIX shares. HC Wainwright boosted their price target on Nurix Therapeutics from $26.00 to $30.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Jefferies Financial Group started coverage on shares of Nurix Therapeutics in a research note on Friday, October 11th. They issued a "buy" rating and a $41.00 target price for the company. Royal Bank of Canada dropped their price target on shares of Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating on the stock in a research note on Monday, October 14th. Oppenheimer upped their price objective on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the stock an "outperform" rating in a report on Wednesday, September 4th. Finally, UBS Group started coverage on Nurix Therapeutics in a report on Thursday, October 24th. They set a "buy" rating and a $35.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $29.40.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.